Valuation: Prothena Corporation plc

Market Cap 441M 386M 357M 327M 620M 42.53B 630M 4.25B 1.67B 20.77B 1.66B 1.62B 71.7B P/E 2026 *
181x
P/E 2027 * -8.18x
Enterprise Value 441M 386M 357M 327M 620M 42.53B 630M 4.25B 1.67B 20.77B 1.66B 1.62B 71.7B EV / Sales 2026 *
5.3x
EV / Sales 2027 * 20.1x
Free-Float
79.82%
Yield 2026 *
-
Yield 2027 * -
1 day-1.90%
1 week-14.00%
Current month-15.32%
3 months-21.20%
6 months-11.34%
Current year-13.19%
1 week 8.08
Extreme 8.075
9.82
1 month 8.08
Extreme 8.075
10.15
Current year 7.73
Extreme 7.73
11.8
1 year 6.24
Extreme 6.24
11.8
3 years 4.32
Extreme 4.32
73.14
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Operating Officer 52 29/09/2021
Director TitleAgeSince
Chairman 76 20/12/2012
Director/Board Member 72 20/12/2012
Director/Board Member 63 20/12/2012
Date Insider Type Main position Quantity % Market Cap.
16/06/26 Buy 20,000 0.0382%
15/06/26 Don -325,000 0.6208%
11/06/26 Buy 125,000 0.2388%
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%-14.00%+31.17%-88.26% 441M
-3.42%+10.05%+58.59%+87.70% 57.82B
-0.05%-5.85%+54.36%+71.44% 53.71B
-3.52%-10.38%+1.33%+411.98% 23.8B
-0.24%-1.26%-18.38%-14.36% 23.26B
-0.56%+10.26%+44.03%-3.86% 20.7B
-0.29%-2.05%+34.41%-29.62% 17.81B
-4.55%-8.65%+194.32%+349.58% 16.9B
-2.61%+8.99%+46.11%+691.67% 16.36B
+0.23%-2.57%+24.15%+189.89% 13.96B
Average -1.70%-0.49%+47.01%+166.62% 24.48B
Weighted average by Cap. -1.73%+0.16%+48.31%+153.64%

Financials

2026 *2027 *
Net sales 83.32M 72.83M 67.35M 61.81M 117M 8.03B 119M 803M 316M 3.92B 313M 306M 13.54B 22M 19.23M 17.78M 16.32M 30.89M 2.12B 31.42M 212M 83.32M 1.04B 82.62M 80.8M 3.57B
Net income 2.42M 2.12M 1.96M 1.8M 3.4M 234M 3.46M 23.36M 9.18M 114M 9.1M 8.9M 394M -55.93M -48.89M -45.21M -41.49M -78.52M -5.39B -79.88M -539M -212M -2.63B -210M -205M -9.09B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
16/07/26 $8.290 -1.66% 241,310
15/07/26 $8.430 -2.43% 504,691
14/07/26 $8.640 -2.15% 530,318
13/07/26 $8.830 -4.44% 781,732
10/07/26 $9.240 -4.15% 505,130
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.430USD
Average target price
21.40USD
Spread / Average Target
+153.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock